The brief

Analyst view

• VK2735 phase 3 VANQUISH trials fully enrolled with ~5,600 patients in obesity and obesity+diabetes cohorts.
• Phase 2 (VENTURE) showed up to 14.7% weight reduction in 13 weeks, dose-dependent.
• Viking is the first to advance both weekly SC and daily oral formulations of a GLP-1/GIP dual into phase 3.

Technical approach

As reported

Dual agonism

GLP-1 and GIP receptor activation

VK2735 activates both GLP-1 (appetite suppression) and GIP (metabolic benefits). Combination maximizes weight loss.

Formulation flexibility

SC injection and oral tablet

Viking develops weekly SC and daily oral forms, giving patients choice and improving compliance.

Dosing strategy

Long-acting depot

Weekly SC dosing reduces injection frequency versus daily oral or twice-weekly competitors.